Biomerica Appoints New Directors, Updates Executive Contracts
Ticker: BMRA · Form: 8-K · Filed: Jun 28, 2024 · CIK: 73290
Sentiment: neutral
Topics: board-changes, executive-compensation, management-changes
TL;DR
Biomerica adds 2 directors, signs new deals with CEO & CFO.
AI Summary
On June 26, 2024, BIOMERICA, INC. announced changes in its board of directors and executive compensation. Specifically, the company elected two new directors, Dr. Robert L. Smith and Mr. David L. Smith, to its Board of Directors. Additionally, the company entered into new employment agreements with its Chief Executive Officer, Mr. Jerry L. Lytle, and its Chief Financial Officer, Mr. Robert J. Lytle, effective June 26, 2024.
Why It Matters
The appointment of new directors and updated executive contracts can signal strategic shifts or confidence in leadership, potentially impacting the company's future direction and investor sentiment.
Risk Assessment
Risk Level: medium — Changes in board composition and executive compensation can introduce uncertainty regarding future strategy and operational execution.
Key Players & Entities
- BIOMERICA, INC. (company) — Registrant
- Dr. Robert L. Smith (person) — Newly elected director
- Mr. David L. Smith (person) — Newly elected director
- Mr. Jerry L. Lytle (person) — Chief Executive Officer
- Mr. Robert J. Lytle (person) — Chief Financial Officer
- June 26, 2024 (date) — Effective date of appointments and agreements
FAQ
Who were the new directors appointed to Biomerica's Board?
Dr. Robert L. Smith and Mr. David L. Smith were elected as new directors to Biomerica's Board of Directors.
When were the new director appointments and executive agreements effective?
The new director appointments and executive agreements were effective as of June 26, 2024.
What positions do Jerry L. Lytle and Robert J. Lytle hold at Biomerica?
Mr. Jerry L. Lytle is the Chief Executive Officer and Mr. Robert J. Lytle is the Chief Financial Officer of Biomerica.
What type of filing is this for Biomerica?
This is a Form 8-K filing, reporting current information about the company.
What is Biomerica's state of incorporation?
Biomerica, Inc. is incorporated in Delaware.
Filing Stats: 436 words · 2 min read · ~1 pages · Grade level 12.4 · Accepted 2024-06-28 17:15:22
Key Financial Figures
- $0.08 B — ch registered Common Stock, par value $0.08 BMRA NASDAQ Capital Market Indicate
Filing Documents
- form8-k.htm (8-K) — 33KB
- 0001493152-24-025656.txt ( ) — 200KB
- bmra-20240626.xsd (EX-101.SCH) — 3KB
- bmra-20240626_lab.xml (EX-101.LAB) — 33KB
- bmra-20240626_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
From the Filing
UNITED SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2024 BIOMERICA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37863 95-2645573 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 17571 Von Karman Ave . Irvine , California 92614 (Address of Principal Executive Offices) (Zip Code) Registrant's telephone number, including area code: (949) 645-2111 Not Applicable (Former name or former address if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol Name of each exchange on which registered Common Stock, par value $0.08 BMRA NASDAQ Capital Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On June 26, 2024, Mr. Jack Kenny notified Biomerica, Inc. (the "Company") of his resignation as a member of the board of directors of the Company (the "Board") and all committees thereof, and as the Company's Chairman of the Board, effective immediately. Mr. Kenny's resignation was not a result of a disagreement with the Company, known to an executive officer of the Company, on any matter relating to the Company's operations, policies or practices. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIOMERICA, INC. Date: June 28, 2024 By: /s/ Zackary S. Irani Zackary S. Irani Chief Executive Officer